Endocrinology and Metabolism (original) (raw)

Table 1 Overview of Recently Published Data on New Antidiabetic Drugs

SGLT2, sodium-glucose cotransporter 2; EMPA-REG, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose; CVD, cardiovascular disease; CANVAS, Canagliflozin Cardiovascular Assessment Study; CV, cardiovascular; DECLARE-TIMI 53, Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 53; GLP-1RA, glucagon-like peptide 1 receptor agonist; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; ACS, acute coronary syndrome; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Semaglutide in Subjects with Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; HARMONY, Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease.

Table 2 Primary Endpoint (Major Adverse Cardiovascular Events) of Completed Trials

PositiveHR, hazard ratio; CI, confidence interval; SGLT2, sodium-glucose cotransporter 2; EMPA-REG, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Temoving Excess Glucose; CANVAS, Canagliflozin Cardiovascular Assessment Study; DECLARE-TIMI 53, Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 53; GLP-1RA, glucagon-like peptide 1 receptor agonist; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Semaglutide in Subjects with Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; HARMONY, Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease.

Table 3 CVOT Results According to Respective Outcomes

CVOT, cardiovascular outcome trial; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; HF, heart failure; EMPA-REG, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Temoving Excess Glucose; CANVAS, Canagliflozin Cardiovascular Assessment Study; DECLARE-TIMI 53, Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 53; ELIXA, Evaluation of Lixisenatide in Acute Coronary Syndrome; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Semaglutide in Subjects with Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering; HARMONY, Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease.